

Expected loss (years)

ER/PR+, HER2-

ER/PR-, HER2-

ER/PR+, HER2+

ER/PR-, HER2+

0.15  
0.10  
0.05  
0.00

0

5

10

15

20

25

30

35

40

0

5

10

15

20

25

30

35

40

0

5

10

15

20

25

30

35

40

0

5

10

15

20

25

30

35

40

Number of visits

stage    I    II    III

0

5

10

15

20

25

30

35

40

0

5

10

15

20

25

30

35

40

0

5

10

15

20

25

30

35

40

0

5

10

15

20

25

30

35

40